23andMe

A massive study finds that regional differences in how slaves were treated throughout the Americas are reflected in the DNA of present-day Americans of African descent.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

Data don’t support many direct-to-consumer products, from telomere assessments to bespoke diets based on genetic sequences.

A security researcher found the email addresses and encrypted passwords of more than 92 million users of the genealogy site on a private server outside the company.

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

Rather, the breast cancer mutation screen was classified as a type of medical device with obligations for the company to reduce risks to customers.

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.

23andMe customers can now receive information about genetic risk for diseases including Parkinson’s and celiac.

Access to data from thousands of genotyping customers helped scientists detect novel associations with the disorder across the genome.

Scientists can now buy the direct-to-consumer sequencing product, and research participants can join 23andMe’s database.

A study identifies genetic variants that are linked to multiple phenotypes.

An analysis of the genomes of nearly 600,000 healthy individuals reveals a handful of people who appear resistant to certain genetic disorders.

In a large genome-wide association study, researchers from 23andMe locate 15 DNA regions associated with people’s preferences for early morning starts.

The personal genomics firm is ramping up its suite of disease-related genetic tests.

The personal genomics firm announces plans to make medicines.

The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.

The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.